At any dose with or without having co-prescriptions.LMP+/-91 days represents

At any dose with or with out co-prescriptions.LMP+/-91 days represents 91 days either side of 1st day of LMP. Exclusions: 1) chromosomal, genetic, teratogenic anomalies; two) exposure during the 91 days either side of LMP to: insulin, AEDs, coumarins. doi:ten.1371/journal.pone.0165122.tBb in S1 Appendix). When Simes’ False Discovery Price procedure was applied, no associations reached the five false discovery price significance level threshold, which includes these with diaphragmatic hernia and syndactyly (Table D in S1 Appendix). When information were re-analysed in Norway and Wales, with these co-prescribed other antidepressants excluded, prevalence rates and ORs changed little (Table C in S1 Appendix). Heterogeneity was low for most outcomes, except CHD and serious CHD (Table 3). The NNH for severe CHD varied: 298 (1721,111) in Denmark, 854 (4004,286) in Wales, and there was no association in Norway.Dose-responseA minority were exposed to prescriptions for higher doses of SSRIs (Table two). Meta-regression for the 3 categories (high, other and zero dose) indicated significant associations for severe CHD and `anomaly or stillbirth’ and non-significant trends for all anomalies and CHD (Table four). Denmark had a greater proportion of each higher dose exposures and severe CHD.Table 2. SSRI exposure 91 days either side of LMPa by person SSRIb and dose: three nations. Denmark Quantity exposed Population Exposed to any SSRI SSRI Fluoxetine Citalopram Paroxetine Sertraline Escitalopram Exposed 1 SSRI Dose High Othera bNorway total exposed one hundred 13.26 40.89 9.07 14.97 11.80 ten.01 21.81 78.19 Number exposed 346,739 5451 509 867 325 804 2750 196 364 5087 one hundred 9.34 15.91 five.96 14.75 50.45 three.60 6.68 93.32 total exposedWales Quantity exposed 115,931 6342 1937 2683 638 395 348 341 810 5532 one hundred 30.54 42.31 10.06 six.23 5.49 five.38 12.77 87.23 total exposedSummed Quantity exposed 519,117 12,962 2601 4028 1069 1374 3236 654 1429 11,533 one hundred 20.07 31.08 eight.25 ten.60 24.97 five.05 11.02 88.98 total exposed56,447 1169 155 478 106 175 138 117 255Exclusions and exposures as Table 1. Fluvoxamine: 28 exposures and 0 exposed cases have been identified, see Table Ba in S1 Appendix.doi:10.1371/journal.pone.0165122.tPLOS A single | DOI:ten.1371/journal.pone.0165122 December 1,eight /Table three. SSRI (NO6AB) exposures 91 days either side of LMPa and outcomesbbased on signals: 3 countries.Denmark exposed n = 1169 n 40 33 5 55 1.37 0.51 181 736 11922 7 ten 6 4 0.03 115 0.05 254 0.08 177 0.03 0.05 0.02 0.06 150 0.03 12 0.22 726 0.21 21 0.Animal-Free IL-2 Protein MedChemExpress 33 295 0.Afamin/AFM Protein Storage & Stability 27 347 0.PMID:23310954 28 1140143 0.23 12 0.22 473 0.14 11 0.17 190 0.17 247 0.19 736 0.15 six 0.11 174 0.05 eight 0.13 80 0.07 158 0.12 275 0.05 98 0.18 9 0.17 567 0.17 19 0.30 200 0.18 34 0.26 865 0.17 447 0.81 44 0.81 3027 0.89 61 0.96 1029 0.94 121 0.93 4503 0.89 1.03 (.86.24) 1.50 (1.06.11) 1.92 (1.13.24) 1.20 (0.79.eight) 1.15 (0.82.61) 1.85 (0.86.96) 1.57 (0.83.98) 0.81 (0.36.82) 0.81 (0.three.21) 6 0.11 271 0.08 ten 0.16 123 0.11 170 0.14 449 0.09 1.43 (0.89.30) 16 6 5 5 five two.82 1255 two.27 149 two.73 8842 2.59 218 three.44 3439 three.14 400 three.09 13,536 2.67 1.09 (0.99.21) 0 0 55.66 51.36 0 0 0 0 0 0 0 three.42 1586 2.87 185 three.39 10412 three.05 248 three.91 3819 three.48 473 3.65 15829 three.13 1.13 (1.03.24) 0 N n N n n n n OR, 95 CIs I2 unexposed n = 55,278 exposedn = 5451 unexposed n = 341,288 exposedn = 6342 Unexposed n = 109,589 exposed n = 12962 unexposed n = 506,155 Meta-analysis Norway Wales SummedAnomaly or stillbirthAll AnomaliesNeural Tube DefectsCHDSevere CHDAbdominal wall defectsc,Talipes equinovarus cHyp.